napsylate


Also found in: Dictionary.

napsylate

 [nap´sĭ-lāt]
USAN contraction for 2-naphthalenesulfonate.

nap·syl·ate

(nap'si-lāt),
USAN-approved contraction for 2-naphthalenesulfonate.

napsylate

/nap·sy·late/ (nap´sĭ-lāt) USAN contraction for 2-naphthalenesulfonate.

napsylate

(năp′sə-lāt′)
n.
A salt of a sulfonic acid of naphthalene, used in the preparation of various pharmaceuticals.

napsylate

USAN contraction for 2-naphthalenesulfonate.
References in periodicals archive ?
announced today that it has commenced nationwide marketing of Darvocet A500(TM) (propoxyphene napsylate and acetaminophen) for the management of mild to moderate pain.
Because the FDA has established a 4,000 mg maximum daily dose of acetaminophen for adults and physicians are concerned about patients who self medicate using over-the-counter products, we believe there is a significant market opportunity for this dose combination which contains less acetaminophen while retaining the full power of propoxyphene napsylate.
Darvocet A500(TM) contains 100 mg of propoxyphene napsylate and 500 mg of acetaminophen compared to the Darvocet-N(R) 100 presentation, which contains 100 mg of propoxyphene and 650 mg of acetaminophen.
has reached an agreement with the FDA to keep propoxyphene-containing products Darvon(R) (propoxyphene hydrochloride), Darvon-N(R) (propoxyphene napsylate), Darvocet-N(R) 50 & Darvocet-N(R) 100 (propoxyphene napsylate and acetaminophen) available as treatment options for the management of mild to moderate pain.
OTCBB:ABRX), today announced it has received Food and Drug Administration (FDA) approval for its Abbreviated New Drug Application (ANDA) for Propoxyphene Napsylate and Acetaminophen Tablets USP 100 mg and 650 mg.
the Triangle-based specialty pharmaceutical company currently focused on the development and commercialization of niche prescription medications in the pain, anti-infective, and respiratory markets, announced that BALACET 325(TM) (100 mg propoxyphene napsylate and 325 mg acetaminophen) Tablets (CIV) was approved by the Food and Drug Administration (FDA) for the treatment of mild to moderate pain in patients 18 years of age and older.
IVAX Corporation (AMEX:IVX) today announced that it has been granted a supplemental approval by the United States Food and Drug Administration (FDA) for propoxephene napsylate and acetaminophen,USP in 100 mg/650 mg pink tablet form.
Acquired, received FDA approval of and launched Darvocet A500(TM) (propoxyphene napsylate and acetaminophen) for the management of mild to moderate pain.